Long lasting heat shock stimulation of TRAIL-induced apoptosis in transformed T lymphocytes

Experimental Cell Research

Volumn 312, Issue 10, 2006, Pages 1765-1784

  Moulin, Maryline ^a   Arrigo, André Patrick ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 8; CELL ANTIBODY; CYTOKINE RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; HEAT SHOCK PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBODY DETECTION; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; HEAT SHOCK; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTE; T LYMPHOCYTE;

EID: 33646830837     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.02.008     Document Type: Article

References (86)

1. Peto J. Cancer epidemiology in the last century and the next decade. Nature 411 (2001) 390-395
2. Ponder B.A. Cancer genetics. Nature 411 (2001) 336-341
3. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
4. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 (2001) 2603-2614
5. Debatin K.M., Poncet D., and Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21 (2002) 8786-8803
6. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16
7. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
8. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
9. Zimmermann K.C., Bonzon C., and Green D.R. The machinery of programmed cell death. Pharmacol. Ther. 92 (2001) 57-70
10. Gregory C.D., and Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?. Immunology 113 (2004) 1-14
11. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17 (1999) 2941
12. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
13. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
14. Loo G., Lippens S., Hahne M., Matthijssens F., Declercq W., Saelens X., and Vandenabeele P. A Bcl-2 transgene expressed in hepatocytes does not protect mice from fulminant liver destruction induced by Fas ligand. Cytokine 22 (2003) 62-70
15. Wajant H., Pfizenmaier K., and Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7 (2002) 449-459
16. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
17. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
18. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 (2000) 564-567
19. Hao C., Song J.H., Hsi B., Lewis J., Song D.K., Petruk K.C., Tyrrell D.L., and Kneteman N.M. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64 (2004) 8502-8506
20. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., and Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7 (2001) 954-960
21. Kimberley F.C., and Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14 (2004) 359-372
22. Tibbetts M.D., Zheng L., and Lenardo M.J. The death effector domain protein family: regulators of cellular homeostasis. Nat. Immunol. 4 (2003) 404-409
23. Juo P., Kuo C.J., Yuan J., and Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 8 (1998) 1001-1008
24. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., and Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
25. Juo P., Woo M.S., Kuo C.J., Signorelli P., Biemann H.P., Hannun Y.A., and Blenis J. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 10 (1999) 797-804
26. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
27. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem. Soc. Symp. 66 (1999) 1-15
28. van Loo G., Saelens X., van Gurp M., MacFarlane M., Martin S.J., and Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 9 (2002) 1031-1042
29. Zou H., Li Y., Liu X., and Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274 (1999) 11549-11556
30. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev., Mol. Cell Biol. 3 (2002) 401-410
31. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., Lee J.H., Lee S.K., Lee S.N., Jung S.S., et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61 (2001) 4942-4946
32. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
33. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., and Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
34. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., Peter M.E., and Yang X. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21 (2002) 3704-3714
35. Fulda S., and Debatin K.M. Modulation of TRAIL signaling for cancer therapy. Vitam. Horm. 67 (2004) 275-290
36. Fulda S., and Debatin K.M. Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta 1705 (2004) 27-41
37. Jin Z., Dicker D.T., and El-Deiry W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1 (2002) 82-89
38. Fulda S., and Debatin K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23 (2004) 6702-6711
39. Delmas D., Rebe C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., and Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 (2004) 8979-8986
40. Fulda S., Jeremias I., and Debatin K.M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 23 (2004) 7611-7620
41. Hahn G.M. Potential for therapy of drugs and hyperthermia. Cancer Res. 39 (1979) 2264-2268
42. Hahn G.M., and Li G.C. Interactions of hyperthermia and drugs: treatments and probes. Natl. Cancer Inst. Monogr. 61 (1982) 317-323
43. Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., Felix R., and Schlag P.M. Hyperthermia in combined treatment of cancer. Lancet Oncol. 3 (2002) 487-497
44. Roti Roti J.L. Introduction: radiosensitization by hyperthermia. Int. J. Hypertherm. 20 (2004) 109-114
45. Levine E.M., and Robbins E.B. Differential temperature sensitivity of normal and cancer cells in culture. J. Cell. Physiol. 76 (1970) 373-379
46. Fabre-Jonca N., Gonin S., Diaz-Latoud C., Rouault J.P., and Arrigo A.P. Thermal sensitivity in NIH 3T3 fibroblasts transformed by the v-fos oncogene. Correlation with reduced accumulation of 68-kDa and 25-kDa stress proteins after heat shock. Eur. J. Biochem. 232 (1995) 118-128
47. Gonin S., Fabre-Jonca N., Diaz-Latoud C., Rouault J.P., and Arrigo A.P. Transformation by T-antigen and other oncogenes delays Hsp25 accumulation in heat shocked NIH 3T3 fibroblasts. Cell Stress Chaperones 2 (1997) 238-251
48. Samali A., and Orrenius S. Heat shock proteins: regulators of stress response and apoptosis. Cell Stress Chaperones 3 (1998) 228-236
49. Arrigo A.P. sHsp as novel regulators of programmed cell death and tumorigenicity. Pathol. Biol. (Paris) 48 (2000) 280-288
50. Mosser D.D., Caron A.W., Bourget L., Meriin A.B., Sherman M.Y., Morimoto R.I., and Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell. Biol. 20 (2000) 7146-7159
51. Bruey J.M., Ducasse C., Bonniaud P., Ravagnan L., Susin S.A., Diaz-Latoud C., Gurbuxani S., Arrigo A.P., Kroemer G., Solary E., and Garrido C. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2 (2000) 645-652
52. Paul C., Manero F., Gonin S., Kretz-Remy C., Virot S., and Arrigo A.P. Hsp27 as a negative regulator of cytochrome c release. Mol. Cell. Biol. 22 (2002) 816-834
53. Hahn G.M., and Li G.C. Thermotolerance and heat shock proteins in mammalian cells. Radiat. Res. 92 (1982) 452-457
54. Hildebrandt B., Wust P., Ahlers O., Dieing A., Sreenivasa G., Kerner T., Felix R., and Riess H. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol./Hematol. 43 (2002) 33-56
55. Creagh E.M., Carmody R.J., and Cotter T.G. Heat shock protein 70 inhibits caspase-dependent and -independent apoptosis in Jurkat T cells. Exp. Cell Res. 257 (2000) 58-66
56. Hermisson M., Wagenknecht B., Wolburg H., Glaser T., Dichgans J., and Weller M. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. Oncogene 19 (2000) 2338-2345
57. Tran S.E., Meinander A., Holmstrom T.H., Rivero-Muller A., Heiskanen K.M., Linnau E.K., Courtney M.J., Mosser D.D., Sistonen L., and Eriksson J.E. Heat stress downregulates FLIP and sensitizes cells to Fas receptor-mediated apoptosis. Cell Death Differ. 10 (2003) 1137-1147
58. Liossis S.N., Ding X.Z., Kiang J.G., and Tsokos G.C. Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J. Immunol. 158 (1997) 5668-5675
59. Clemons N.J., Buzzard K., Steel R., and Anderson R.L. Hsp72 inhibits Fas-mediated apoptosis upstream of the mitochondria in type II cells. J. Biol. Chem. 280 (2005) 9005-9012
60. Ozoren N., and El-Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp. Cell Res. 281 (2002) 175-181
61. Manero F., Ljubic-Thibal V., Moulin M., Goutagny N., Yvin J.C., and Arrigo A.P. Stimulation of Fas agonistic antibody-mediated apoptosis by heparin-like agents suppresses Hsp27 but not Bcl-2 protective activity. Cell Stress Chaperones 9 (2004) 150-166
62. Scaffidi C., Schmitz I., Krammer P.H., and Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274 (1999) 1541-1548
63. Krueger A., Fas S.C., Baumann S., and Krammer P.H. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol. Rev. 193 (2003) 58-69
64. Kreuz S., Siegmund D., Scheurich P., and Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21 (2001) 3964-3973
65. Neckers L., Mimnaugh E., and Schulte T.W. Hsp90 as an anti-cancer target. Drug Resist. Updat. 2 (1999) 165-172
66. Uehara Y. Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets 3 (2003) 325-330
67. Kuhl N.M., Kunz J., and Rensing L. Heat shock-induced arrests in different cell cycle phases of rat C6-glioma cells are attenuated in heat shock-primed thermotolerant cells. Cell Proliferation 33 (2000) 147-166
68. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., and Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
69. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., and Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2 (2000) 241-243
70. Siegmund D., Hadwiger P., Pfizenmaier K., Vornlocher H.P., and Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol. Med. 8 (2002) 725-732
71. Gajate C., and Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98 (2001) 3860-3863
72. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., Laurent G., Gambert P., Solary E., and Dimanche-Boitrel M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64 (2004) 3593-3598
73. Vanoosten R.L., Moore J.M., Ludwig A.T., and Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 11 (2005) 542-552
74. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat. Rev., Mol. Cell Biol. 1 (2000) 31-39
75. Young J.C., Agashe V.R., Siegers K., and Hartl F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev., Mol. Cell Biol. 5 (2004) 781-791
76. Jäättela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248 (1999) 30-43
77. Jaattela M., Wissing D., Bauer P.A., and Li G.C. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J. 11 (1992) 3507-3512
78. Mehlen P., Préville X., Chareyron P., Briolay J., Klemenz R., and Arrigo A.-P. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J. Immunol. 154 (1995) 363-374
79. Dubois M.F., Ferrieux C., and Lebon P. Synergistic cytotoxic effects of recombinant human tumor necrosis factor, interferons, and heat-stress. Cancer Res. 49 (1989) 5618-5622
80. Arrigo A.P., and Michel M.R. Decreased heat- and tumor necrosis factor-mediated hsp28 phosphorylation in thermotolerant HeLa cells. FEBS Lett. 282 (1991) 152-156
81. Ricci J.E., Maulon L., Battaglione-Hofman V., Bertolotto C., Luciano F., Mari B., Hofman P., and Auberger P. A Jurkat T cell variant resistant to death receptor-induced apoptosis. Correlation with heat shock protein (Hsp) 27 and 70 levels. Eur. Cytokine Netw. 12 (2001) 126-134
82. Ma Y.F., Zhang J., Zhao Y.P., Yang D.L., and Chen Y.H. Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells. Zhonghua Zhongliu Zazhi 26 (2004) 528-530
83. Rodenhiser D., Jung J.H., and Atkinson B.G. Mammalian lymphocytes: stress-induced synthesis of heat-shock proteins in vitro and in vivo. Can. J. Biochem. Cell Biol. 63 (1985) 711-722
84. Micheau O., Solary E., Hammann A., and Dimanche-Boitrel M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274 (1999) 7987-7992
85. Tran S.E., Meinander A., and Eriksson J.E. Instant decisions: transcription-independent control of death-receptor-mediated apoptosis. Trends Biochem. Sci. 29 (2004) 601-608
86. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., and Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275 (2000) 23319-23325